**Company Profile**

**Industry Sector:** Medical Devices

**Company Overview:** Bio-Quick Corporation is a start-up company developing pathology instruments and assays based in Silver Spring, Maryland. Bio-Quick’s R&D and business activities aim at significantly improving the speed, cost-effectiveness, and efficiency of pathological research and cancer diagnosis.

**Target Market(s):** hospitals and medical research institutions world wide

---

**Management**

**Leadership:**
Wei-Sing Chu, President and CEO
Andrew Ji, Vice President, Business Development
Feng Tao, Chief Operating Officer
Nianxiang (Nick) Zou, Vice President, IP and R&D

**Scientific Advisory Board:**

---

**Key Value Drivers**

**Technology:** Bio-Quick's proprietary technologies include the ultrasound-facilitated tissue preservation technology (US-FFPE), apparatus and methods for efficient processing of biological samples on slides, and devices and methods for on-slide biomolecule extraction. These innovative technologies, invented by Dr. Wei-Sing Chu, founder of Bio-Quick, have been patented, and Bio-Quick has exclusive license for the rights to commercialize these technologies.

**Competitive Advantage:** The US-FFPE technology can significantly reduce the time needed for the current FFPE protocol from 1-to-2 days down to less than 1 hour. This approach not only maintains the “gold standard” FFPE morphology, but also allows automation and standardization for the tissue fixation and process. In addition, the US-FFPE technology permits precise controls in the biomolecular modification and cross-linking in formalin fixation, so that tissue specimens are “frozen in time” at the point of formalin fixation, preserving the integrity of biomolecules as well as morphological features. This technology has a great potential to minimize pre-analytical variables for downstream assays.

**Plan & Strategy:** seeking a strategic partner
*Technology funded by the National Cancer Institute and being commercialized under the NIH-CAP*

---

**Product Pipeline**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial Source</td>
<td>SBIR Phase I</td>
<td>SBIR Phase II</td>
<td>Private investment</td>
</tr>
<tr>
<td>Production (unit/year)</td>
<td>1-5 investigational devices</td>
<td>20-50 optimized investigational devices</td>
<td>Up to 100 advanced Automatic devices</td>
</tr>
<tr>
<td>Marketing Strategy</td>
<td>Independent</td>
<td>Independent</td>
<td>Partnership</td>
</tr>
</tbody>
</table>

![Timeline](image)